Co-Diagnostics (NasdaqCM:CODX) Q4 2025 Earnings call March 31, 2026 04:30 PM ET Company ParticipantsAndrew Benson - Head of Investor RelationsBrian Brown - CFODwight Egan - CEOConference Call ParticipantsMichael Okunewitch - Senior Analyst of BiotechnologyNone - AnalystOperatorToday's session is being recorded. It is now my pleasure to turn the floor over to Head of Investor Relations, Mr. Andrew Benson. Please go ahead, sir.Andrew BensonGood afternoon, everyone. Thank you all for participating in today's c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number: 001-41173 NexGel, Inc. (Exact name of registrant as specified in its charter) | Delaware | 26-4042544 | | --- | ...

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Coty Inc. (“Coty” or the “Company”) (NYSE: COTY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Coty and certain of its officers and/or ...

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ChowChow Cloud International Holdings Ltd. (“ChowChow” or the “Company”) (NYSE: CHOW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether ChowChow and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the cla ...

TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Allied Gold Corporation (“Allied” or the "Company") (TSX: AAUC) (NYSE: AAUC) is pleased to announce that shareholders of the Company approved the previously announced plan of arrangement (the "Transaction") with Zijin Gold International Company Limited (“Zijin Gold”) at the Company’s special meeting of shareholders held earlier today. At the Meeting, a total of 76,556,033 votes were cast by holders of Common Shares, representing 61.14% of the total issued and outs ...

雅居乐集团 分时图 日K线 周K线 月K线 0.24 -0.01 -2.04% 2.04% 2.04% 2.04% 2.04% 2.04% 2.04% 2.04% 0.24 0.24 0.24 0.24 0.25 0.25 0.25 09:30 10:30 12:00/13:00 14:00 16:10 0 22万 43万 65万 雅居乐集团(03383)发布截至2025年12月31日止年度业绩，该集团取得营业额278.59亿元(人民币，下 同)，同比减少35.73%;股东应占亏损225.69亿元，同比扩大31.09%;每股基本亏损4.473元。 公告称，年内，集团连同其合营企业及联营公司以及由集团管理并以"雅居乐"品牌销售的房地产项目的 预售金额合计为人民币85.7亿元，同比下降44.7%，对应累计预售建筑面积为93.9万平方米，同比下降 19.1%，预售均价为每平方米人民币9129元，同比下降31.7%。销售方面进一步收缩，集团的流动性也 遭受较大影响。 亏损主要受以下因素影响：出售╱终止确认附属公司取得亏损;使用权益法入账的投资减值亏损;及所得 税开支大幅上升。 ...

泰格医药 泰格医药 分时图 日K线 周K线 月K线 53.83 1.15 2.18% 5.73% 3.82% 1.92% 0.00% 1.92% 3.82% 5.73% 49.66 50.67 51.67 52.68 53.69 54.69 55.70 09:30 10:30 11:30/13:00 14:00 15:00 15:30 0 28万 56万 83万 泰格医药（300347）(300347.SZ)发布2025年年度报告，该公司营业收入为68.33亿元，同比增长3.48%。 归属于上市公司股东的净利润为8.88亿元，同比增长119.15%。归属于上市公司股东的扣除非经常性损 益的净利润为3.55亿元，同比减少58.47%。基本每股收益为1.04元。此外，拟向全体股东每10股派发现 金红利1.26元(含税)。 ...

泰格医药 泰格医药 分时图 日K线 周K线 月K线 53.83 1.15 2.18% 5.73% 3.82% 1.92% 0.00% 1.92% 3.82% 5.73% 49.66 50.67 51.67 52.68 53.69 54.69 55.70 09:30 10:30 11:30/13:00 14:00 15:00 15:30 0 28万 56万 83万 泰格医药（300347）(03347)发布截至2025年12月31日止年度业绩，该集团取得营业收入68.33亿元，同 比增加3.48%;归属于上市公司的净利润8.88亿元，同比增加119.15%;基本每股收益1.04元，拟向全体股 东每10股派发现金红利1.26元。 公告称，临床试验技术服务(临床试验技术服务)分部收入为32.67亿元，而同期为31.78亿元。临床试验 相关服务及实验室服务(临床试验相关服务及实验室服务)分部收入由同期的34.25亿元同比增加4.1%至 35.66亿元。 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41378 CARTESIAN GROWTH CORPORATION II Indicate by check mark whether the registrant has submitted electronically e ...